Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

Jan 07, 2013, 14:48 ET from Reportlinker

NEW YORK, Jan. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

http://www.reportlinker.com/p0191858/Pharmaceuticals---BRIC-Brazil-Russia-India-China-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report * Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $101.8 billion in 2011. China was the fastest growing country with a CAGR of 20.6% over the 2007-11 period.

Within the pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of $55.4 billion in 2011.

China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $108.1 billion in 2016, followed by Brazil, India, Russia with expected values of $29.0, $27.3 and $24.9 billion, respectively.

Why you should buy this report * Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.TABLE OF CONTENTSIntroduction 10What is this report about? 10Who is the target reader? 10How to use this report 10Definitions 10BRIC Pharmaceuticals Industry Outlook 11Pharmaceuticals in Brazil 15Market Overview 15Market Data 16Market Segmentation 17Market outlook 19Five forces analysis 20Leading companies 28Macroeconomic indicators 34Pharmaceuticals in China 36Market Overview 36Market Data 37Market Segmentation 38Market outlook 40Five forces analysis 41Leading companies 49Macroeconomic indicators 57Pharmaceuticals in India 59Market Overview 59Market Data 60Market Segmentation 61Market outlook 63Five forces analysis 64Leading companies 72Macroeconomic indicators 85Pharmaceuticals in Russia 87Market Overview 87Market Data 88Market Segmentation 89Market outlook 91Five forces analysis 92Leading companies 100Macroeconomic indicators 113Appendix 115Methodology 115

LIST OF TABLES

Table 1: BRIC pharmaceuticals industry, revenue($bn), 2007-16 11

Table 2: BRIC pharmaceuticals industry, revenue($bn), 2007-11 13

Table 3: BRIC pharmaceuticals industry, revenue($bn), 2007-11 14

Table 4: Brazil pharmaceuticals market value: $ billion, 2007–11 16

Table 5: Brazil pharmaceuticals market geography segmentation: $ billion, 2011 17

Table 6: Brazil pharmaceuticals market share: % share, by value, 2011 18

Table 7: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 19

Table 8: Aché Laboratórios Farmacêuticos S.A.: key facts 28

Table 9: Medley Indústria Farmacêutica Ltd: key facts 29

Table 10: Sanofi: key facts 30

Table 11: Sanofi: key financials ($) 31

Table 12: Sanofi: key financials (€) 31

Table 13: Sanofi: key financial ratios 31

Table 14: EMS Sigma Pharma: key facts 33

Table 15: Brazil size of population (million), 2007–11 34

Table 16: Brazil gdp (constant 2000 prices, $ billion), 2007–11 34

Table 17: Brazil gdp (current prices, $ billion), 2007–11 34

Table 18: Brazil inflation, 2007–11 35

Table 19: Brazil consumer price index (absolute), 2007–11 35

Table 20: Brazil exchange rate, 2007–11 35

Table 21: China pharmaceuticals market value: $ billion, 2007–11 37

Table 22: China pharmaceuticals market geography segmentation: $ billion, 2011 38

Table 23: China pharmaceuticals market share: % share, by value, 2011 39

Table 24: China pharmaceuticals market value forecast: $ billion, 2011–16 40

Table 25: Pfizer Inc.: key facts 49

Table 26: Pfizer Inc.: key financials ($) 50

Table 27: Pfizer Inc.: key financial ratios 50

Table 28: AstraZeneca PLC: key facts 52

Table 29: AstraZeneca PLC: key financials ($) 53

Table 30: AstraZeneca PLC: key financial ratios 54

Table 31: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 56

Table 32: China size of population (million), 2007–11 57

Table 33: China gdp (constant 2000 prices, $ billion), 2007–11 57

Table 34: China gdp (current prices, $ billion), 2007–11 57

Table 35: China inflation, 2007–11 58

Table 36: China consumer price index (absolute), 2007–11 58

Table 37: China exchange rate, 2007–11 58

Table 38: India pharmaceuticals market value: $ billion, 2007–11 60

Table 39: India pharmaceuticals market geography segmentation: $ billion, 2011 61

Table 40: India pharmaceuticals market share: % share, by value, 2011 62

Table 41: India pharmaceuticals market value forecast: $ billion, 2011–16 63

Table 42: Dr. Reddy's Laboratories Limited: key facts 72

Table 43: Dr. Reddy's Laboratories Limited: key financials ($) 73

Table 44: Dr. Reddy's Laboratories Limited: key financials (Rs.) 73

Table 45: Dr. Reddy's Laboratories Limited: key financial ratios 73

Table 46: Cipla Limited: key facts 75

Table 47: Cipla Limited: key financials ($) 76

Table 48: Cipla Limited: key financials (Rs.) 76

Table 49: Cipla Limited: key financial ratios 76

Table 50: Ranbaxy Laboratories Limited: key facts 78

Table 51: Ranbaxy Laboratories Limited: key financials ($) 79

Table 52: Ranbaxy Laboratories Limited: key financials (Rs.) 79

Table 53: Ranbaxy Laboratories Limited: key financial ratios 79

Table 54: Lupin Limited: key facts 81

Table 55: Lupin Limited: key financials ($) 82

Table 56: Lupin Limited: key financials (Rs.) 82

Table 57: Lupin Limited: key financial ratios 83

Table 58: India size of population (million), 2007–11 85

Table 59: India gdp (constant 2000 prices, $ billion), 2007–11 85

Table 60: India gdp (current prices, $ billion), 2007–11 85

Table 61: India inflation, 2007–11 86

Table 62: India consumer price index (absolute), 2007–11 86

Table 63: India exchange rate, 2007–11 86

Table 64: Russia pharmaceuticals market value: $ billion, 2007–11 88

Table 65: Russia pharmaceuticals market geography segmentation: $ billion, 2011 89

Table 66: Russia pharmaceuticals market share: % share, by value, 2011 90

Table 67: Russia pharmaceuticals market value forecast: $ billion, 2011–16 91

Table 68: Pharmstandard OJSC: key facts 100

Table 69: Pharmstandard OJSC: key financials ($) 100

Table 70: Pharmstandard OJSC: key financials (RUB) 101

Table 71: Pharmstandard OJSC: key financial ratios 101

Table 72: Sanofi: key facts 103

Table 73: Sanofi: key financials ($) 104

Table 74: Sanofi: key financials (€) 104

Table 75: Sanofi: key financial ratios 104

Table 76: Novartis AG: key facts 106

Table 77: Novartis AG: key financials ($) 107

Table 78: Novartis AG: key financial ratios 107

Table 79: Bayer AG: key facts 109

Table 80: Bayer AG: key financials ($) 110

Table 81: Bayer AG: key financials (€) 110

Table 82: Bayer AG: key financial ratios 111

Table 83: Russia size of population (million), 2007–11 113

Table 84: Russia gdp (constant 2000 prices, $ billion), 2007–11 113

Table 85: Russia gdp (current prices, $ billion), 2007–11 113

Table 86: Russia inflation, 2007–11 114

Table 87: Russia consumer price index (absolute), 2007–11 114

Table 88: Russia exchange rate, 2007–11 114

LIST OF FIGURES

Figure 1: BRIC pharmaceuticals industry, revenue($bn), 2007-16 11Figure 2: BRIC pharmaceuticals industry, revenue($bn), 2007-11 13Figure 3: BRIC pharmaceuticals industry, revenue($bn), 2007-11 14Figure 4: Brazil pharmaceuticals market value: $ billion, 2007–11 16Figure 5: Brazil pharmaceuticals market geography segmentation: % share, by value, 2011 17Figure 6: Brazil pharmaceuticals market share: % share, by value, 2011 18Figure 7: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 19Figure 8: Forces driving competition in the pharmaceuticals market in Brazil, 2011 20Figure 9: Drivers of buyer power in the pharmaceuticals market in Brazil, 2011 21Figure 10: Drivers of supplier power in the pharmaceuticals market in Brazil, 2011 23Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2011 24Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2011 26Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2011 27Figure 14: Sanofi: revenues & profitability 32Figure 15: Sanofi: assets & liabilities 32Figure 16: China pharmaceuticals market value: $ billion, 2007–11 37Figure 17: China pharmaceuticals market geography segmentation: % share, by value, 2011 38Figure 18: China pharmaceuticals market share: % share, by value, 2011 39Figure 19: China pharmaceuticals market value forecast: $ billion, 2011–16 40Figure 20: Forces driving competition in the pharmaceuticals market in China, 2011 41Figure 21: Drivers of buyer power in the pharmaceuticals market in China, 2011 42Figure 22: Drivers of supplier power in the pharmaceuticals market in China, 2011 44Figure 23: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2011 45Figure 24: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2011 47Figure 25: Drivers of degree of rivalry in the pharmaceuticals market in China, 2011 48Figure 26: Pfizer Inc.: revenues & profitability 51Figure 27: Pfizer Inc.: assets & liabilities 51Figure 28: AstraZeneca PLC: revenues & profitability 54Figure 29: AstraZeneca PLC: assets & liabilities 55Figure 30: India pharmaceuticals market value: $ billion, 2007–11 60Figure 31: India pharmaceuticals market geography segmentation: % share, by value, 2011 61Figure 32: India pharmaceuticals market share: % share, by value, 2011 62Figure 33: India pharmaceuticals market value forecast: $ billion, 2011–16 63Figure 34: Forces driving competition in the pharmaceuticals market in India, 2011 64Figure 35: Drivers of buyer power in the pharmaceuticals market in India, 2011 65Figure 36: Drivers of supplier power in the pharmaceuticals market in India, 2011 67Figure 37: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2011 68Figure 38: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2011 70Figure 39: Drivers of degree of rivalry in the pharmaceuticals market in India, 2011 71Figure 40: Dr. Reddy's Laboratories Limited: revenues & profitability 74Figure 41: Dr. Reddy's Laboratories Limited: assets & liabilities 74Figure 42: Cipla Limited: revenues & profitability 77Figure 43: Cipla Limited: assets & liabilities 77Figure 44: Ranbaxy Laboratories Limited: revenues & profitability 80Figure 45: Ranbaxy Laboratories Limited: assets & liabilities 80Figure 46: Lupin Limited: revenues & profitability 83Figure 47: Lupin Limited: assets & liabilities 84Figure 48: Russia pharmaceuticals market value: $ billion, 2007–11 88Figure 49: Russia pharmaceuticals market geography segmentation: % share, by value, 2011 89Figure 50: Russia pharmaceuticals market share: % share, by value, 2011 90Figure 51: Russia pharmaceuticals market value forecast: $ billion, 2011–16 91Figure 52: Forces driving competition in the pharmaceuticals market in Russia, 2011 92Figure 53: Drivers of buyer power in the pharmaceuticals market in Russia, 2011 93Figure 54: Drivers of supplier power in the pharmaceuticals market in Russia, 2011 95Figure 55: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011 96Figure 56: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011 98Figure 57: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011 99Figure 58: Pharmstandard OJSC: revenues & profitability 101Figure 59: Pharmstandard OJSC: assets & liabilities 102Figure 60: Sanofi: revenues & profitability 105Figure 61: Sanofi: assets & liabilities 105Figure 62: Novartis AG: revenues & profitability 108Figure 63: Novartis AG: assets & liabilities 108Figure 64: Bayer AG: revenues & profitability 111Figure 65: Bayer AG: assets & liabilities 112

To order this report:Pharmaceutical Industry: Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

CONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com